Loading...
•
Dec 31, 2022
Maravai Q4 2022 Earnings Report
Reported financial results for the fourth quarter and full year, with base business revenues, excluding COVID-19 related CleanCap® revenues, up 67% in the fourth quarter.
Key Takeaways
Maravai LifeSciences reported a decrease in revenue for the fourth quarter, driven by a decline in Nucleic Acid Production revenue due to decreased CleanCap demand. However, base Nucleic Acid Production revenue increased significantly. Net income and Adjusted EBITDA also decreased compared to the same period in the prior year.
Quarterly revenue reached $204.7 million and net income reached $87.4 million.
Adjusted fully diluted earnings per share (EPS) of $0.35.
Base Nucleic Acid Production revenue was up 101% over the same period in the prior year.
Acquired Alphazyme, LLC to add critical enzyme manufacturing capabilities to Maravai’s Nucleic Acid Production Segment.
Maravai
Maravai
Maravai Revenue by Segment
Revenue by Segment
Nucleic Acid Production Revenue
CapyFin.comBiologics Safety Testing Revenue
CapyFin.com Forward Guidance
Maravai expects total revenue for 2023 to be in the range of $420.0 million to $460.0 million, including an estimate of $100.0 million of CleanCap revenue. Adjusted fully diluted EPS is expected to be in the range of $0.32 - $0.38 per share.
Positive Outlook
- Base business revenues, excluding COVID-19 related CleanCap revenues, expected to grow in excess of 20%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income